Novo Nordisk has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more and more heated.

The Trump administration is nearing deals with drugmakers Eli Lilly and Novo Nordisk to offer some of their obesity drugs to consumers for as low as $149 per month, according to two people familiar ...

Novo Nordisk’s latest offer is more than 30% above what Pfizer initially agreed to pay for the obesity biotech Metsera, not ...

The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

The White House is nearing an agreement with pharmaceutical companies Novo Nordisk and Eli Lilly to offer some of their ...

Shares of Hims & Hers Health ($HIMS) rallied on Tuesday after management said it’s in discussions with Novo Nordisk ($NVO) to ...

Taking a closer look at the numbers, Comirnaty sales slipped 19% globally to $1.15 billion, the Prevnar franchise experienced a 3% global sales decline to $1.7 billion, and Abrysvo’s performance ...

The bidding war for US obesity focused biotech Metsera, which has attracted offers from Pfizer and Novo Nordisk , and ...

Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO ...

The competition between Pfizer and Novo Nordisk over obesity drug developer Metsera escalated, with Novo's $10 billion offering deemed superior. Despite legal challenges from Pfizer, Novo continues to ...

Pfizer and Novo Nordisk's fight for obesity drug developer Metsera ratcheted up on Tuesday as both companies submitted ...

Hims & Hers continues to sell compounded semaglutide, the active ingredient in Novo’s Wegovy and Ozempic drugs, and these ...